The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

被引:0
作者
N. Zethraeus
O. Ström
F. Borgström
J. A. Kanis
B. Jönsson
机构
[1] Stockholm School of Economics,Centre for Health Economics
[2] European Health Economics,Centre for Metabolic Bone Diseases (WHO Collaborating Centre)
[3] Medical Management Centre at the Karolinska Institutet (KI),undefined
[4] University of Sheffield Medical School,undefined
[5] UK,undefined
来源
Osteoporosis International | 2008年 / 19卷
关键词
Bisphosphonates; Cost; Hydrochlorthiazides; QALY; Statins;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:819 / 827
页数:8
相关论文
共 103 条
[1]  
Zethraeus N(2007)Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model Osteoporos Int 18 9-23
[2]  
Borgstrom F(2002)Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis Osteoporos Int 13 841-857
[3]  
Strom O(2006)Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature Osteoporos Int 17 29-40
[4]  
Kanis JA(2004)Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial JAMA 291 1701-1712
[5]  
Zethraeus N(2002)Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial JAMA 288 321-333
[6]  
Ben Sedrine W(2005)Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial Int J Technol Assess Health Care 21 433-441
[7]  
Caulin F(2006)Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927-2938
[8]  
Corcaud S(2002)Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 137 875-883
[9]  
Fleurence RL(2004)Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995 Atheroscler Suppl 5 91-97
[10]  
Iglesias CP(1993)Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease Arch Intern Med 153 578-581